Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1995 1
2003 1
2005 1
2006 1
2008 1
2009 1
2010 1
2011 2
2012 1
2013 2
2014 2
2015 1
2016 11
2017 9
2018 11
2019 6
2020 16
2021 15
2022 14
2023 20
2024 16
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Results by year

Filters applied: . Clear all
Page 1
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.
Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, Quaratino S, Wilson R, Grievink HW, Klaassen ES, Bergmann KR, Burggraaf J, van Doorn MBA, Powell J, Moerland M, Rissmann R. Saghari M, et al. Among authors: van doorn mba. Clin Pharmacol Ther. 2022 May;111(5):1121-1132. doi: 10.1002/cpt.2539. Epub 2022 Mar 1. Clin Pharmacol Ther. 2022. PMID: 35092305 Free PMC article. Clinical Trial.
Complement Activation in Inflammatory Skin Diseases.
Giang J, Seelen MAJ, van Doorn MBA, Rissmann R, Prens EP, Damman J. Giang J, et al. Among authors: van doorn mba. Front Immunol. 2018 Apr 16;9:639. doi: 10.3389/fimmu.2018.00639. eCollection 2018. Front Immunol. 2018. PMID: 29713318 Free PMC article. Review.
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Porras NM, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Sevimli Dikicier B, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. Among authors: van doorn mba. JAMA Dermatol. 2024 Sep 1;160(9):927-935. doi: 10.1001/jamadermatol.2024.2056. JAMA Dermatol. 2024. PMID: 39018068
KECORT Study: An International e-Delphi Study on the Treatment of KEloids Using Intralesional CORTicosteroids in Clinical Practice.
Yin Q, Wolkerstorfer A, Lapid O, Qayumi K, Alam M, Al-Niaimi F, Artzi O, van Doorn MBA, Goutos I, Haedersdal M, Hsu CK, Manuskiatti W, Monstrey S, Mustoe TA, Ogawa R, Ozog D, Park TH, Pötschke J, Rossi A, Tan ST, Téot L, Wood FM, Yu N, Gibbs S, Niessen FB, van Zuijlen PPM. Yin Q, et al. Among authors: van doorn mba. Am J Clin Dermatol. 2024 Nov;25(6):1009-1017. doi: 10.1007/s40257-024-00888-7. Epub 2024 Sep 19. Am J Clin Dermatol. 2024. PMID: 39298112 Free PMC article.
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Thomas SE, Seyger MMB, Mangnus JE, Otero ME, Gostynski AH, Njoo MD, Ossenkoppele PM, Haeck IM, Hendricksen-Roelofzen JHJ, Körver JEM, Dodemont SRP, Tupker RA, Berends MAM, Weppner-Parren LMJT, Keijsers RRMC, Oostveen AM, Peters B, Mommers R, van Doorn MBA, Tjioe M, Veldkamp WR, Kuijpers ALA, Kleinpenning MM, de Jong EMGJ, van den Reek JMPA. Thomas SE, et al. Among authors: van doorn mba. Am J Clin Dermatol. 2024 Jul;25(4):685-688. doi: 10.1007/s40257-024-00868-x. Epub 2024 May 27. Am J Clin Dermatol. 2024. PMID: 38802618 No abstract available.
Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX).
Perez-Garcia LF, Röder E, Krijthe BP, Kranenburg-van Koppen LJ, van Adrichem R, Zirkzee E, Griffioen PH, Peeters K, Lin M, Struys EA, Jansen G, van Doorn MB, de Jonge R, Dohle GR, Dolhain RJ. Perez-Garcia LF, et al. Among authors: van doorn mb. Ann Rheum Dis. 2023 Aug;82(8):1068-1075. doi: 10.1136/ard-2023-224032. Epub 2023 Jun 1. Ann Rheum Dis. 2023. PMID: 37263756 Free PMC article.
Similar Alterations of the Stratum Corneum Ceramide Profile in Atopic Dermatitis, Psoriasis, and Ichthyosis: Results from a Systematic Review and Meta-Analysis.
Rousel J, Mergen C, Schoones JW, Niemeyer-van der Kolk T, van Doorn MBA, Bouwstra JA, van Smeden J, Rissmann R; Next Generation ImmunoDermatology Consortium. Rousel J, et al. Among authors: van doorn mba. J Invest Dermatol. 2024 Oct;144(10):2311-2314.e22. doi: 10.1016/j.jid.2024.02.010. Epub 2024 Mar 4. J Invest Dermatol. 2024. PMID: 38447864 Free article. No abstract available.
Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three-year follow-up data of a single-blind randomized controlled trial.
van Huizen AM, van der Kraaij GE, Busard CI, Ouwerkerk W, van den Reek JMPA, Menting SP, Prens EP, Rispens T, de Vries A, de Jong EMGJ, Lambert J, van Doorn MBA, Spuls PI. van Huizen AM, et al. Among authors: van doorn mba. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1815-1824. doi: 10.1111/jdv.19089. Epub 2023 Apr 17. J Eur Acad Dermatol Venereol. 2023. PMID: 37014287 Clinical Trial.
114 results